Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20889505 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Guo H, et al. (2010) Osteopontin and protein kinase C regulate PDLIM2 activation and STAT1 ubiquitination in LPS-treated murine macrophages. J Biol Chem 285, 37787-96 20889505
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S137-p - PDLIM2 (mouse)
Orthologous residues
PDLIM2 (human): S137‑p, PDLIM2 iso3 (human): S137‑p, PDLIM2 (mouse): S137‑p, PDLIM2 (rat): S137‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry, mutation of modification site
 Relevant cell lines - cell types - tissues:  macrophage-peritoneum, RAW 264.7 (macrophage)
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE PKCA (human)
KINASE PKCA (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKCA (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS osteopontin (human) increase
Go 6850 LPS osteopontin (human) inhibit treatment-induced increase
Go 6976 LPS osteopontin (human) inhibit treatment-induced increase
4-cyano-3-methylisoquinoline LPS osteopontin (human) no effect upon treatment-induced increase
p38 MAP kinase inhibitor III LPS osteopontin (human) no effect upon treatment-induced increase
LY294002 LPS osteopontin (human) no effect upon treatment-induced increase
U0126 LPS osteopontin (human) no effect upon treatment-induced increase
rottlerin LPS osteopontin (human) no effect upon treatment-induced increase
PKCI 19-36 LPS osteopontin (human) no effect upon treatment-induced increase
Go 6850 decrease
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced, ubiquitination
 Comments:  PDLIM2 is STAT1 ubiquitin E3 ligase

T138-p - PDLIM2 (mouse)
Orthologous residues
PDLIM2 (human): P138‑p, PDLIM2 iso3 (human): P138‑p, PDLIM2 (mouse): T138‑p, PDLIM2 (rat): T138‑p
Characterization
 Methods used to characterize site in vivo mass spectrometry, mutation of modification site
 Relevant cell lines - cell types - tissues:  macrophage-peritoneum, RAW 264.7 (macrophage)
 Cellular systems studied:  cell lines
 Species studied:  mouse


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.